A post hoc analysis of the PARADIGM study showed that patients achieving a significant decrease in NT-proBNP levels had lower rates of subsequent cardiovascular death or heart failure hospitalization regardless of their treatment group.12 The gene discussed is NPPB; the disease is heart failure.